Credit: Fresenius Kabi. Conexxence and Bomyntra were approved by the FDA in March 2025. The interchangeability designation allows the biosimilars to be substituted for the reference product at the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback